NCT04520451View on ClinicalTrials.gov

Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Participants

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

August 22, 2020

Primary Completion Date

October 15, 2024

Study Completion Date

October 15, 2024

Conditions
Immunoglobulin G4 Related Disease
Interventions
DRUG

rilzabrutinib

oral tablet

DRUG

Glucocorticoids

oral tablet or capsule

Trial Locations (9)

10021

Investigational Site Number 84030, New York

48202

Investigational Site Number 84018, Detroit

94305

Investigational Site Number 84019, Stanford

97239

Investigational Site Number 84036, Portland

02114

Investigational Site Number 84016, Boston

V6K 2V8

Investigational Site Number 12403, Vancouver

Unknown

Investigational Site Number 25013, Marseille

Investigational Site Number 38016, Milan

Investigational Site Number 72415, Barcelona

All Listed Sponsors
collaborator

Massachusetts General Hospital

OTHER

lead

Principia Biopharma, a Sanofi Company

INDUSTRY

NCT04520451 - Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Participants | Biotech Hunter | Biotech Hunter